UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 837

Sortiert nach

A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

European journal of cancer (1990), 2014-04, Vol.50 (6), p.1084-1089

2014

Volltextzugriff (PDF)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

British journal of cancer, 2013-06, Vol.108 (12), p.2470-2477

2013

Volltextzugriff (PDF)

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Annals of oncology, 2014-01, Vol.25 (1), p.149-154

2014

Volltextzugriff (PDF)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

British journal of cancer, 2014-06, Vol.110 (12), p.2821-2828

2014

Volltextzugriff (PDF)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

British journal of cancer, 2014-04, Vol.110 (8), p.1917-1922

2014

Volltextzugriff (PDF)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

British journal of cancer, 2014-03, Vol.110 (5), p.1125-1132

2014

Volltextzugriff (PDF)

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

Annals of oncology, 2008-02, Vol.19 (2), p.265-268

2008

Volltextzugriff (PDF)

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

Annals of oncology, 2011-01, Vol.22 (1), p.145-148

2011

Volltextzugriff (PDF)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Annals of oncology, 2020-08, Vol.31 (8), p.1030-1039

2020

Volltextzugriff (PDF)

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

Annals of oncology, 2015-07, Vol.26 (7), p.1300-1304

2015

Volltextzugriff (PDF)

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Annals of oncology, 2015-07, Vol.26 (7), p.1372-1377

2015

Volltextzugriff (PDF)

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma

Annals of oncology, 2007-02, Vol.18 (2), p.249-255

2007

Volltextzugriff (PDF)

Recent Progress in the Management of Advanced Renal Cell Carcinoma

CA: a cancer journal for clinicians, 2007-03, Vol.57 (2), p.112-125

2007

Volltextzugriff (PDF)

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Annals of oncology, 2012-06, Vol.23 (6), p.1549-1555

2012

Volltextzugriff (PDF)

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2018-10, Vol.29, p.viii724-viii725

2018

Volltextzugriff (PDF)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

ESMO open, 2021-02, Vol.6 (1), p.100030, Article 100030

2021

Volltextzugriff (PDF)

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial

ESMO open, 2021-06, Vol.6 (3), p.100101, Article 100101

2021

Volltextzugriff (PDF)

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Annals of oncology, 2018-10, Vol.29, p.viii724-viii724

2018

Volltextzugriff (PDF)

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

ESMO open, 2022-04, Vol.7 (2), p.100450-100450, Article 100450

2022

Volltextzugriff (PDF)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

ESMO open, 2023-06, Vol.8 (3), p.101210-101210, Article 101210

2023

Volltextzugriff (PDF)

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience

Bone marrow transplantation (Basingstoke), 2005-02, Vol.35 (3), p.253-260

2005

Volltextzugriff (PDF)

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer

Journal of clinical oncology, 2000-06, Vol.18 (12), p.2419-2426

2000

Volltextzugriff (PDF)

The clinical impact of targeted next generation sequencing (tNGS) in the treatment of metastatic prostate cancer

Annals of oncology, 2018-10, Vol.29, p.viii295-viii295

2018

Volltextzugriff (PDF)

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

Annals of oncology, 2018-10, Vol.29, p.viii309-viii309

2018

Volltextzugriff (PDF)

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

ESMO open, 2023-12, Vol.8 (6), p.102034-102034, Article 102034

2023

Volltextzugriff (PDF)

1 – 25 von 837

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(713)
Mit Volltextzugriff
(735)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(382)
Life Sciences & Biomedicine
(323)
Humans
(311)
Female
(190)
Male
(184)
Middle Aged
(153)
Adult
(140)
Oncology
(132)
Aged
(109)
Biological And Medical Sciences
(98)
Medical Sciences
(89)
Carcinoma, Renal Cell - Drug Therapy
(76)
Kidney Neoplasms - Drug Therapy
(69)
Kidney Neoplasms - Pathology
(55)
Renal Cell Carcinoma
(54)
Tumors
(48)
Treatment Outcome
(45)
Carcinoma, Renal Cell - Pathology
(41)
Aged, 80 And Over
(40)
Patients
(40)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma

Recent Progress in the Management of Advanced Renal Cell Carcinoma

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer

The clinical impact of targeted next generation sequencing (tNGS) in the treatment of metastatic prostate cancer

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Suchergebnisse filtern